Difference between revisions of "Luspatercept (Reblozyl)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the NCI Drug Dictionary: A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor t...") |
m (→Also known as) |
||
| Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' ACE-536 | *'''Code name:''' ACE-536 | ||
| + | *'''Generic name:''' luspatercept-aamt | ||
*'''Brand name:''' Reblozyl | *'''Brand name:''' Reblozyl | ||
Revision as of 15:38, 23 January 2020
Mechanism of action
From the NCI Drug Dictionary: A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. Luspatercept acts at a different, later stage than erythropoietin.
Diseases for which it is used
History of changes in FDA indication
Also known as
- Code name: ACE-536
- Generic name: luspatercept-aamt
- Brand name: Reblozyl